trending Market Intelligence /marketintelligence/en/news-insights/trending/b-YHcZBpIav9FKTbBnYHZA2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Lupin gets warning from US FDA after inspection of Mandideep facility

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Lupin gets warning from US FDA after inspection of Mandideep facility

Lupin Ltd. said the U.S. Food and Drug Administration recommended taking action against the company after inspecting its Mandideep facility in Madhya Pradesh, India.

Following the December inspection, the regulator warned the Indian drugmaker that it may withhold approval of its pending applications or supplements related to the facility.

The Mumbai-based company said no applications related to the facility are pending with the FDA and the warning will not have any impact on revenues and operations from the facility.

The maker of generic drugs added that it will send updates of its corrective actions to the agency and expects a positive outcome.